Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus

• Published in: Journal of Diabetes Research Vol. 2019; no. 2019; pp. 1 - 7
• Main Authors: Hasegawa, Koji, Morimoto, Tatsuya, Wada, Hiromichi, Yamakage, Hajime, Kakeya, Hideaki, Miyazaki, Yusuke, Katanasaka, Yasufumi, Sunagawa, Yoichi, Shimizu, Kana, Funamoto, Masafumi, Satoh-Asahara, Noriko
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc; Wiley
• Subjects: Aqueous solutions; Atherosclerosis; Cardiovascular disease; Clinical Study; Coronary heart disease; Dextrose; Diabetes; Diabetes therapy; Diabetics; Glucose; Glycosylated hemoglobin; Heart attacks; Heart failure; Insulin; Insulin resistance; Low density lipoproteins; Males; Metabolism; Patients; Type 2 diabetes; Japan
• ISSN: 2314-6745; 2314-6753; 2314-6753
• DOI: 10.1155/2019/8208237

Oxidative stress is enhanced by various mechanisms. Serum oxidized low-density lipoprotein (LDL) is a useful prognostic marker in diabetic patients with coronary artery disease. To examine the effects of Theracurmin®, a highly absorbable curcumin preparation, on glucose tolerance, adipocytokines, and oxidized LDL, we conducted a double-blind placebo-controlled parallel group randomized trial in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. We randomly divided the patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus and stable individuals into the placebo group and the Theracurmin® (180 mg daily for 6 months) group. Of the 33 patients analyzed, 18 (14 males and 4 females) were administered placebo and 15 (9 males and 6 females) were administered Theracurmin®. The patient characteristics did not differ between the two groups. The primary endpoint, HbA1c, did not differ significantly between the two groups. However, the level of α1-antitrypsin-low-density lipoprotein (AT-LDL), the oxidized LDL, significantly increased (p=0.024) in the placebo group from the beginning of the trial up to 6 months, although there was no such change in the Theracurmin® group. The percentage change in BMI from the beginning of the trial up to 6 months tended to be higher in the Theracurmin® group than in the placebo group. Patients in the Theracurmin® group tended to have a larger percentage change in adiponectin and LDL-C than those in the placebo group. Patients in the Theracurmin® group showed a smaller percentage change in AT-LDL than those in the placebo group. This study suggests that the highly absorbable curcumin could potentially inhibit a rise in oxidized LDL in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. This trial is registered with UMIN000007361.